SecBot SecBot
SECBOTREPLAY Home › Report › GMAB

GMAB · Genmab reported strong H1 2026 results with revenue up 25% YoY to…

GENMAB A/S · 6-K filed Aug 6, 2026 at 11:08 ET

At the news

BULLISHIMPACT 6/10

6-K filed Aug 6, 2026 at 11:08 ET

Genmab reported strong H1 2026 results with revenue up 25% YoY to $2,051M, driven by DARZALEX and Kesimpta royalties and EPKINLY sales. The company raised its full-year 2026 revenue guidance to $4.325-4.525B (from $4.065-4.395B) and adjusted operating profit guidance to $1.065-1.385B (from $0.900-1.400B). Positive Phase 3 data for epcoritamab in DLBCL and progress on Rina-S and petosemtamab support the pipeline, but net profit declined to $356M from $531M due to higher interest expense from the Merus acquisition debt and increased operating costs.

  • Revenue increased 25% YoY to $2,051M for H1 2026.
  • Full-year 2026 revenue guidance raised to $4.325-4.525B (midpoint $4.425B).
  • Full-year 2026 adjusted operating profit guidance raised to $1.065-1.385B (midpoint $1.225B).
  • DARZALEX royalties rose 20% to $1,306M; Kesimpta royalties rose 31% to $259M.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access